Abstract

Etravirine (Intelence; Tibotec) is a non-nucleoside inhibitor of HIV-1 reverse transcriptase. In January 2008, it was approved by the US FDA for the treatment of HIV-1 infection in combination with other antiretroviral agents for treatment-experienced patients who have HIV-1 strains that are resistant to other drugs in this class.

Author affiliations

1. Richard Haubrich is at the Division of Infectious Diseases, University of California, San Diego, Antiviral Research Center, 150 West Washington Street, Suite 100 San Diego, California 92103, USA.
   Email: rhaubrich@ucsd.edu
2. Steven Gubernick and Uma Yasothan are at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.
   Email: UYasothan@de.imshealth.com
3. Peter Kirkpatrick is at Nature Reviews Drug Discovery.
   Email: p.kirkpatrick@nature.com

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.